Journal of Current Glaucoma Practice

Register      Login

VOLUME 13 , ISSUE 3 ( September-December, 2019 ) > List of Articles

Original Article

CyPass® Micro-Stent Safety and Efficacy at One Year: What Have We Learned?

Itay E Gabbay, Simon Ruben

Keywords : CyPass®, Glaucoma, Intraocular pressure, Suprachoroidal

Citation Information : Gabbay IE, Ruben S. CyPass® Micro-Stent Safety and Efficacy at One Year: What Have We Learned?. J Curr Glaucoma Pract 2019; 13 (3):99-103.

DOI: 10.5005/jp-journals-10078-1264

License: CC BY-NC 4.0

Published Online: 01-04-2020

Copyright Statement:  Copyright © 2019; The Author(s).


Purpose: The suprachoroidal pathway can potentially provide a viable target for intraocular pressure (IOP) control. We present efficacy and safety result for the CyPass® Micro-Stent that provides insight into the use of the suprachoroidal space for IOP reduction. Materials and methods: A retrospective, noncomparative audit of patient records in a university-affiliated National Health Service (NHS) hospital between June 2017 and August 2018. Main outcome measures were IOP reduction and the number of glaucoma drops taken at each time point. Failure and adverse events were noted for each patient. Results: Seventy-seven consecutive case records of 69 patients underwent the CyPass® procedure between August 2017 and August 2018. A stand-alone procedure was performed in 37 (58%) of cases and combined phacoemulsification and CyPass® procedures were performed in 27 (42%) of cases. At baseline, the mean IOP was 24.6 ± 7.2 mm Hg. The mean IOP at 12 months’ follow-up was 16.4 ± 4.5 mm Hg (p < 0.05). At baseline, the mean number of medications was 2.41 ± 0.98, which decreased at 12 months to 1.1 ± 1.3 (p < 0.05). Best corrected visual acuity analysis did not show statistically significant change preoperatively and at each postoperative time point. At 12 months’ postoperative time point, 24% of eyes had failed. Significant IOP spikes were noted in 18 (28.1%) of cases. Conclusion: The suprachoroidal pathway appears to potentially offer an alternative to the classic subconjunctival pathways, yet present a new set of challenges. Further studies would have to address these concerns of endothelial cell loss, IOP spikes, and high failure rate.

  1. Bunce C, Wormald R. Causes of blind certifications in England and Wales: April 1999-March 2000. Eye (Lond) 2008;22(7):905–911. DOI: 10.1038/sj.eye.6702767.
  2. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol 2002;120(10):1268–1279. DOI: 10.1001/archopht.120.10.1268.
  3. Schwartz GF. Compliance and persistency in glaucoma follow-up treatment. Curr Opin Ophthalmol 2005;16(2):114–121. DOI: 10.1097/
  4. Kerr NM, Wang J, Barton K. Minimally invasive glaucoma surgery as primary stand-alone surgery for glaucoma. Clin Exp Ophthalmol 2017;45(4):393–400. DOI: 10.1111/ceo.12888.
  5. Hoeh H, Vold SD, Ahmed IK, et al. Initial clinical experience with the CyPass Micro-Stent: safety and surgical outcomes of a novel supraciliary microstent. J Glaucoma 2016;25(1):106–112. DOI: 10.1097/IJG.0000000000000134.
  6. Pfeiffer N, Garcia-Feijoo J, Martinez-de-la-Casa JM, et al. A randomized trial of a Schlemm's canal Microstent with phacoemulsification for reducing intraocular pressure in open-angle glaucoma. Ophthalmology 2015;122(7):1283–1293. DOI: 10.1016/j.ophtha.2015.03.031.
  7. Arriola-Villalobos P, Martínez-de-la-Casa JM, Díaz-Valle D, et al. Combined iStent trabecular micro-bypass stent implantation and phacoemulsification for coexistent open-angle glaucoma and cataract: a long-term study. Br J Ophthalmol 2012;96(5):645–649. DOI: 10.1136/bjophthalmol-2011-300218.
  8. Vold S, Ahmed IIK, Craven ER, et al. Two-year COMPASS trial results: supraciliary Microstenting with phacoemulsification in patients with open-angle glaucoma and cataracts. Ophthalmology 2016;123(10):2103–2112. DOI: 10.1016/j.ophtha.2016.06.032.
  9. Craven ER, Katz LJ, Wells JM, et al. Cataract surgery with trabecular micro-bypass stent implantation in patients with mild-to-moderate open-angle glaucoma and cataract: two-year follow-up. J Cataract Refract Surg 2012;38(8):1339–1345. DOI: 10.1016/j.jcrs.2012.03.025.
  10. Hoeh H, Ahmed IIK, Grisanti S, et al. Early postoperative safety and surgical outcomes after implantation of a suprachoroidal Micro-Stent for the treatment of open-angle glaucoma concomitant with cataract surgery. J Cataract Refract Surg 2013;39(3):431–437. DOI: 10.1016/j.jcrs.2012.10.040.
  11. García-Feijoo J, Rau M, Grisanti S, et al. Supraciliary Micro-Stent implantation for open-angle glaucoma failing topical therapy: 1-year results of a Multicenter study. Am J Ophthalmol 2015;159(6): 1075.e1–1081.e1. DOI: 10.1016/j.ajo.2015.02.018.
  12. Höh H, Grisanti S, Grisanti S, et al. Two-year clinical experience with the CyPass Micro-Stent: safety and surgical outcomes of a novel supraciliary Micro-Stent. Klin Monatsbl Augenheilkd 2014;231(4): 377–381. DOI: 10.1055/s-0034-1368214.
  13. González-Martín-Moro J, Contreras-Martín I, Muñoz-Negrete FJ, et al. Cyclodialysis: an update. Int Ophthalmol 2017;37(2):441–457. DOI: 10.1007/s10792-016-0282-8.
  14. Barkan O, Boyle SF, Maisler S. On the surgery of glaucoma: mode of action of cyclodialysis. Calif West Med 1936;44(1):12–16. DOI: 10.1016/S0002-9394(36)95189-9.
  15. Sédan J. The present development of cyclodialysis from 1905 to 1967. Ann Ocul (Paris) 1967;200(3):293–306.
  16. Barkan O. Cyclodialysis, multiple or single, with air injection-an operative technique for chronic glaucoma. Calif Med 1947;67(2): 78–83. DOI: 10.1016/0002-9394(47)91090-8.
  17. Dada T, Sharma R, Sinha G, et al. Cyclodialysis-wnhanced trabeculectomy with triple Ologen implantation. Eur J Ophthalmol 2016;26(1):95–97. DOI: 10.5301/ejo.5000633.
  18. Skalicky SE, Lew HR. Surgical outcomes of combined trabeculectomy-cyclodialysis for glaucoma. J Glaucoma 2015;24(1):37–44. DOI: 10.1097/IJG.0b013e3182883c44.
  19. Brubaker RF, Pederson JE. Ciliochoroidal detachment. Surv Ophthalmol 1983;27(5):281–289. DOI: 10.1016/0039-6257(83)90228-X.
  20. Ormerod LD, Baerveldt G, Sunalp MA, et al. Management of the hypotonous cyclodialysis cleft. Ophthalmology 1991;98(9):1384–1393. DOI: 10.1016/S0161-6420(91)32121-3.
  21. Malandrini A, Balestrazzi A, Martone G, et al. Diagnosis and management of traumatic cyclodialysis cleft. J Cataract Refract Surg 2008;34(7):1213–1216. DOI: 10.1016/j.jcrs.2008.02.038.
  22. Melamed S, Ben Simon GJ, Goldenfeld M, et al. Efficacy and safety of gold micro shunt implantation to the supraciliary space in patients with glaucoma: a pilot study. Arch Ophthalmol 2009;127(3):264–269. DOI: 10.1001/archophthalmol.2008.611.
  23. Cseke I, Vámosi P, Bausz M. Starflo glaucoma implant: early experience in Hungary. Rom J Ophthalmol 2016;60(1):14–17.
  24. Figus M, Lazzeri S, Fogagnolo P, et al. Supraciliary shunt in refractory glaucoma. Br J Ophthalmol 2011;95(11):1537–1541. DOI: 10.1136/bjophthalmol-2011-300308.
  25. Fili S, Seddig S, Papadopoulou E, et al. 1-Jahres-Ergebnisse nach Cypass-implantation [one-year results after Cypass implantation]. Ophthalmologe 2019;116(5):447–455. DOI: 10.1007/s00347-018- 0745-6.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.